BioNTech price target lowered to $90 from $115 at HSBC

HSBC lowered the firm’s price target on BioNTech to $90 from $115 and keeps a Hold rating on the shares. The analyst says with a broad range of pipeline assets to offset the COVID-19 revenue cliff, BioNTech’s research and development productivity “becomes crucial.”